Stryker Corporation (SYK) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extrem...
Stryker Corporation's revenue increased 11.2% year over year, from $22.59B to $25.12B.
Net income increased 8.5% over the same period, from $2.99B to $3.25B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 122% in total.
Total debt increased by 16.6% to $15.86B.
The debt-to-equity ratio stands at 0.71, indicating a moderate leverage profile.
Operating cash flow grew 18.9% to $5.04B.
Stryker Corporation maintains a healthy net profit margin of 12.9%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $14.68B+50.2% | $2.02B | $9.36B | $2.63B | $2.18B | $38.04B | $12.69B | $17.91B |
| Q1 FY2024 | $5.24B-64.3% | $788.0M | $3.33B | $972.0M | $204.0M | $39.40B | $12.87B | $19.17B |
| Q2 FY2024 | $10.66B+103.4% | $1.61B | $6.75B | $2.02B | $837.0M | $39.13B | $12.22B | $19.76B |
| Q3 FY2024 | $16.16B+51.5% | $2.45B | $10.27B | $3.11B | $2.31B | $43.83B | $15.48B | $20.15B |
| Q1 FY2025 | $5.87B-63.7% | $654.0M | $3.74B | $837.0M | $250.0M | $46.01B | $16.78B | $20.93B |
| Q2 FY2025 | $11.89B+102.7% | $1.54B | $7.58B | $1.95B | $1.36B | $46.33B | $16.58B | $21.19B |
| Q3 FY2025 | $17.95B+51.0% | $2.40B | $11.44B | $3.08B | $2.90B | $47.06B | $16.59B | $21.79B |
| Q1 FY2026 | $6.02B-66.5% | $745.0M | $3.81B | $936.0M | $581.0M | $46.29B | $14.72B | $22.98B |
Balance Sheet Summary (Latest Period)
Total Assets
$47.84B
Total Liabilities
$25.42B
Total Equity
$22.42B
Cash & Equivalents
$4.10B
Total Debt
$15.86B
Current Assets
$14.76B
Current Liabilities
$7.79B
Retained Earnings
$20.47B